PUBLISHER: The Business Research Company | PRODUCT CODE: 1760694
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760694
Pneumoconiosis refers to a group of lung diseases resulting from the prolonged inhalation of certain types of dust, leading to inflammation and scarring in the lung tissue. This damage can hinder the lungs' ability to efficiently exchange oxygen, causing symptoms such as shortness of breath, persistent coughing, and reduced exercise tolerance.
The primary types of pneumoconiosis include asbestosis, berylliosis, byssinosis, coal workers' pneumoconiosis, silicosis, and others. Asbestosis is a chronic condition caused by the prolonged inhalation of asbestos fibers. Treatment options for pneumoconiosis include medications, oxygen therapy, pulmonary rehabilitation, and others. These treatments may be administered orally, through inhalation, or other methods, while diagnostic approaches involve chest X-rays, computed tomography (CT) scans, lung function tests, and bronchoscopy. Various healthcare providers, such as hospitals, specialty clinics, and diagnostic centers, serve as end users for these treatments and diagnostic procedures.
The pneumoconiosis market research report is one of a series of new reports from The Business Research Company that provides pneumoconiosis market statistics, including the pneumoconiosis industry global market size, regional shares, competitors with the pneumoconiosis market share, detailed pneumoconiosis market segments, market trends, and opportunities, and any further data you may need to thrive in the pneumoconiosis industry. This pneumoconiosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pneumoconiosis market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing occupational exposure to coal dust, rising mining activities in unregulated regions, increasing neglect of worker health policies, growing delays in disease diagnosis, and rising cases of untreated respiratory issues.
The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth projected for the forecast period is driven by an increased focus on occupational health standards, stricter enforcement of dust control regulations, more investments in worker safety initiatives, greater awareness of pneumoconiosis risks, and improved access to early diagnostic services. Key trends anticipated during the forecast period include advancements in lung imaging technologies, innovations in portable respiratory devices, developments in AI-driven disease detection, increased funding for research into dust-related health issues, and advancements in wearable air quality monitoring sensors.
The widespread prevalence of smoking is expected to drive the growth of the pneumoconiosis market. Smoking involves inhaling and exhaling the smoke from burning tobacco products such as cigarettes, cigars, or pipes, which releases harmful chemicals that negatively impact the lungs, heart, and overall health. The rising prevalence of smoking is linked to increasing nicotine dependence and continued tobacco use across various age groups. Smoking contributes to pneumoconiosis by raising the incidence of lung diseases related to smoking. For example, in June 2023, The Guardian reported that 14.5% of 14 to 17-year-olds in the UK had used vaping products in early 2023, an increase from 11.8% in 2022. This growing smoking rate is driving the pneumoconiosis market forward.
Increasing healthcare expenditures are expected to contribute to the growth of the pneumoconiosis market. Healthcare expenditures represent the total financial outlay on medical services, treatments, and health-related products by individuals, governments, and organizations. The rising healthcare spending is mainly due to the growing incidence of chronic diseases, which require ongoing treatment and management. These expenditures support pneumoconiosis care by financing early diagnoses, continuous medical care, respiratory therapy, and access to specialized treatments and medications. For example, the Office for National Statistics reported in May 2024 that healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will accelerate the pneumoconiosis market's growth.
Leading companies in the pneumoconiosis market are focusing on the development of targeted drugs, such as oral small molecule drugs, to offer innovative treatment options that improve disease management and enhance the quality of life for those affected by occupational lung diseases. Oral small molecule drugs are made from low molecular weight compounds that can be ingested, absorbed into the bloodstream, and designed to target specific biological processes or proteins to treat diseases. For instance, in March 2022, Sino Biopharmaceutical Limited launched TDI01 suspension, a novel oral small molecule drug targeting ROCK2 for pneumoconiosis treatment. This groundbreaking drug, currently undergoing clinical trials, aims to offer a much-needed therapeutic option for the 900,000 people with pneumoconiosis in China, a condition that previously had no effective treatment.
Major players in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Gilead Sciences, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Veracyte Inc., Fidia Farmaceutici, PharmaMar, Verastem Inc., RS Oncology, Melinta Therapeutics LLC, Lupin
North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumoconiosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pneumoconiosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pneumoconiosis market consists of sales of protective equipment, diagnostic imaging systems, and therapeutic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pneumoconiosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pneumoconiosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pneumoconiosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumoconiosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.